www.longitudecapital.com Open in urlscan Pro
104.197.16.200  Public Scan

Form analysis
2 forms found in the DOM

GET https://www.longitudecapital.com/

<form role="search" method="get" class="et-search-form c-logo-active" action="https://www.longitudecapital.com/"> <input type="search" class="et-search-field c-logo-active" placeholder="Search …" value="" name="s" title="Search for:"></form>

POST /#gf_1

<form method="post" enctype="multipart/form-data" target="gform_ajax_frame_1" id="gform_1" action="/#gf_1" class="c-logo-active">
  <div class="gform_body gform-body c-logo-active">
    <ul id="gform_fields_1" class="gform_fields top_label form_sublabel_below description_below c-logo-active">
      <li id="field_1_4" class="gfield gfield_contains_required field_sublabel_below field_description_below gfield_visibility_visible c-logo-active" data-js-reload="field_1_4"><label class="gfield_label screen-reader-text c-logo-active"
          for="input_1_4">Name<span class="gfield_required c-logo-active"><span class="gfield_required gfield_required_asterisk c-logo-active">*</span></span></label>
        <div class="ginput_container ginput_container_text c-logo-active"><input name="input_4" id="input_1_4" type="text" value="" class="large c-logo-active" tabindex="99" placeholder="Name" aria-required="true" aria-invalid="false"></div>
      </li>
      <li id="field_1_2" class="gfield gfield_contains_required field_sublabel_below field_description_below gfield_visibility_visible c-logo-active" data-js-reload="field_1_2"><label class="gfield_label screen-reader-text c-logo-active"
          for="input_1_2">Email<span class="gfield_required c-logo-active"><span class="gfield_required gfield_required_asterisk c-logo-active">*</span></span></label>
        <div class="ginput_container ginput_container_email c-logo-active"> <input name="input_2" id="input_1_2" type="text" value="" class="large c-logo-active" tabindex="100" placeholder="Email" aria-required="true" aria-invalid="false"></div>
      </li>
      <li id="field_1_3" class="gfield field_sublabel_below field_description_below gfield_visibility_visible c-logo-active" data-js-reload="field_1_3"><label class="gfield_label screen-reader-text c-logo-active" for="input_1_3">Comment</label>
        <div class="ginput_container ginput_container_textarea c-logo-active"><textarea name="input_3" id="input_1_3" class="textarea large c-logo-active" tabindex="101" placeholder="Comment" aria-invalid="false" rows="10" cols="50"></textarea></div>
      </li>
    </ul>
  </div>
  <div class="gform_footer top_label c-logo-active"> <input type="submit" id="gform_submit_button_1" class="gform_button button c-logo-active" value="Submit" tabindex="102"
      onclick="if(window[&quot;gf_submitting_1&quot;]){return false;}  window[&quot;gf_submitting_1&quot;]=true;  "
      onkeypress="if( event.keyCode == 13 ){ if(window[&quot;gf_submitting_1&quot;]){return false;} window[&quot;gf_submitting_1&quot;]=true;  jQuery(&quot;#gform_1&quot;).trigger(&quot;submit&quot;,[true]); }"> <input type="hidden" name="gform_ajax"
      value="form_id=1&amp;title=&amp;description=&amp;tabindex=99" class="c-logo-active"> <input type="hidden" class="gform_hidden c-logo-active" name="is_submit_1" value="1"> <input type="hidden" class="gform_hidden c-logo-active"
      name="gform_submit" value="1"> <input type="hidden" class="gform_hidden c-logo-active" name="gform_unique_id" value=""> <input type="hidden" class="gform_hidden c-logo-active" name="state_1"
      value="WyJbXSIsIjNlMzZjMmQzZjEwNTFiMDYzNTRlZWMxNjJhYWM0NTRjIl0="> <input type="hidden" class="gform_hidden c-logo-active" name="gform_target_page_number_1" id="gform_target_page_number_1" value="0"> <input type="hidden"
      class="gform_hidden c-logo-active" name="gform_source_page_number_1" id="gform_source_page_number_1" value="1"> <input type="hidden" name="gform_field_values" value="" class="c-logo-active"></div>
  <p style="display: none !important;" class="c-logo-active"><label class="c-logo-active">Δ<textarea name="ak_hp_textarea" cols="45" rows="8" maxlength="100" class="c-logo-active"></textarea></label><input type="hidden" id="ak_js_1" name="ak_js"
      value="1717074687590" class="c-logo-active">
    <script class="c-logo-active">
      document.getElementById("ak_js_1").setAttribute("value", (new Date()).getTime());
    </script>
  </p>
</form>

Text Content

 * ABOUT
 * TEAM
 * PORTFOLIO
 * NEWS
 * CONTACT
 * LP LOGIN

Select Page
 * ABOUT
 * TEAM
 * PORTFOLIO
 * NEWS
 * CONTACT
 * LP LOGIN




INVESTING IN TRANSFORMATIVE
HEALTHCARE COMPANIES.


STRATEGY & APPROACH

Longitude Capital specializes in making venture growth investments in
biotechnology, medical technology, and health solutions companies that seek to
improve clinical outcomes, enhance patient quality of life, and reduce the cost
of care. We invest in both privately held and publicly traded companies through
a variety of investment approaches. Since 2006, Longitude Capital has raised
over $2 billion across six funds and demonstrated an ability to source, manage,
and exit attractive investments across multiple market cycles.

Our venture growth strategy is rooted in building a balanced portfolio of
clinical-stage and commercial-stage companies with clinically de-risked assets,
favorable valuations relative to risk profile, and attractive expected returns
within three to five years from initial investment.

Longitude Capital seeks to identify new investment opportunities by tapping into
our broad network of industry relationships

or through the execution of proprietary thematic research into emerging
therapeutic areas or industry sub-sectors. We utilize a variety of investment
structures, including traditional venture capital, asset spin-outs,
recapitalizations, PIPEs, open market purchases, royalties, and other equity and
equity-linked instruments.

Following an initial investment, we work closely with our portfolio companies
and syndicate partners to develop and implement strategic plans, achieve key
operating objectives, build world-class teams, raise capital, and pursue
liquidity opportunities in a manner that optimizes returns to key stakeholders.

Our company name was inspired by the Longitude Prize, a competition established
by the British monarchy in 1714 to solve one of the greatest scientific problems
of the day.


OUR TEAM,
YOUR PARTNERS

Longitude Capital’s founders have been investing together since 2002. Our team
has over 200 years of combined investing experience in the life sciences
industry and has collaborated on over 90 new investments and 150 follow-on
investments in the biotechnology, medical technology, and health solutions
sectors. We operate from our offices in Menlo Park, California, Greenwich,
Connecticut and Boston, Massachusetts.


LEADERSHIP



 * JULIET
   
   BAKKER

 * MAXWELL
   
   BIKOFF

 * PATRICK
   
   ENRIGHT

 * MARC
   
   GALLETTI

   JULIET
   BAKKER
   
   Managing Director
   
   Ms. Bakker is a Managing Director and Founder of Longitude Capital. Prior to
   Longitude Capital, Ms. Bakker was a Managing Director of Pequot Ventures,
   where she founded the life sciences investment practice. Prior to Pequot, she
   was Director, Strategic Planning and Director, Operations of Waste Management
   International, and was a sell-side equity analyst with Banque Paribas. Ms.
   Bakker began her career as an investment banker in the corporate finance
   department at PaineWebber. She currently serves on the boards of Ceribell,
   Endogenex, Nalu, RxSight (RXST), Sydnexis, and an undisclosed medical
   technology company. Selected prior board memberships include Ablation
   Frontiers (acquired by Medtronic), Alphaeon, AqueSys (acquired by Allergan),
   Axonics Modulation Technologies (AXNX), CryoVascular Systems (acquired by
   Boston Scientific), Eargo (EAR), Embolic Protection (acquired by Boston
   Scientific), Enteric Medical (acquired by Boston Scientific), eyeonics
   (acquired by Bausch+Lomb), Genyx Medical (acquired by C.R. Bard), Insulet
   (PODD), Precision Dermatology (acquired by Valeant Pharmaceuticals), Sadra
   Medical (acquired by Boston Scientific), and Venus Concept (VERO). Ms. Bakker
   holds an MPA from the Harvard Kennedy School and a BSc from the College of
   Agriculture and Life Sciences (”CALS”) at Cornell University, where she is a
   member of the CALS Advisory Council.
   —
   Focus Areas: Medical Technology, Health Solutions
   Location: Greenwich

   MAXWELL
   BIKOFF
   
   Managing Director
   
   Mr. Bikoff is a Managing Director at Longitude Capital. Prior to joining
   Longitude Capital in 2016, Mr. Bikoff held a series of strategy, finance, and
   operating roles at Cardinal Health. While at Cardinal Health, he worked to
   deploy over $6 billion of capital through M&A and minority investments. Most
   recently, Mr. Bikoff was the Director of North America Marketing for the
   Cordis cardiovascular franchise. Mr. Bikoff currently serves on the board of
   Polares Medical and is a board observer at Ceribell and an undisclosed
   medical technology company. He previously served as a board observer at
   Amphora (acquired), Eargo (EAR), Endogenex, LimFlow (acquired by Inari
   Medical), Nalu Medical, and RxSight (RXST), and was also actively involved in
   Longitude Capital’s investment in Axonics Modulation Technologies (AXNX) and
   PROCEPT BioRobotics (PRCT). Mr. Bikoff began his career in Deloitte
   Consulting’s Life Sciences Strategy practice and holds a BSE in Biomedical
   Engineering from Duke University.
   —
   Focus Areas: Medical Technology
   Location: Menlo Park

   PATRICK
   ENRIGHT
   
   Managing Director
   
   Mr. Enright is a Managing Director and Founder of Longitude Capital. Prior to
   Longitude Capital, Mr. Enright was a Managing Director of Pequot Ventures,
   where he co-led the life sciences investment practice. Prior to Pequot, he
   was a Managing Member of the Delta Opportunity Fund at Diaz & Altschul
   Capital Management. Mr. Enright began his investment career at PaineWebber
   Development Corporation. Mr. Enright also has significant life sciences
   operations experience, including senior executive positions at Valentis
   (VLTS), Boehringer Mannheim (acquired by Roche), and Sandoz (now known as
   Novartis). Mr. Enright currently serves on the boards of CuraSen
   Therapeutics, Endeavor Biomedicines, Epirium Bio, Jazz Pharmaceuticals
   (JAZZ), Opna Bio, Orbus Therapeutics, Vera Therapeutics (VERA), and Zenas
   BioPharma. Selected prior board memberships include Aimmune (AIMT, acquired
   by Nestlé), Codexis (CDXS), Corcept Therapeutics (CORT), Esperion
   Therapeutics (ESPR), Horizon Pharmaceuticals (HZNP), InfaCare Pharmaceutical
   (acquired by Mallinckrodt), MAP Pharmaceuticals (MAPP, acquired by Allergan),
   Prestwick Pharmaceuticals (acquired by Lundbeck), Rivus Pharmaceuticals,
   Sequenom (SQNM, acquired by LabCorp), Threshold Pharmaceuticals (THLD),
   Vaxcyte (PCVX), as well as the National Venture Capital Association (NVCA).
   Mr. Enright holds an MBA from the Wharton School of Business at the
   University of Pennsylvania and a BS in Biological Sciences from Stanford
   University.
   —
   Focus Areas: Biotechnology, Health Solutions
   Location: Menlo Park

   MARC
   GALLETTI
   
   Managing Director
   
   Mr. Galletti is a Managing Director and Founder of Longitude Capital. Prior
   to Longitude Capital, Mr. Galletti was a Senior Vice President of Pequot
   Ventures, where he worked in the life sciences practice. Prior to Pequot
   Ventures, Mr. Galletti worked at Amerindo Investment Advisors, Vector Fund
   Management, and the Global Healthcare Investment Banking Group at J.P. Morgan
   & Co. Mr. Galletti began his career in the life sciences industry at APM, a
   management consultancy dedicated to improving operations performance within
   the patient care and procedural units of large acute-care hospitals. Mr.
   Galletti currently serves on the board of Murj. Selected prior board
   memberships include Amphora Medical (acquired), Aptus Endosystems (acquired
   by Medtronic), and Twelve (acquired by Medtronic), and he has also been
   involved with prior investments in Ablation Frontiers (acquired by
   Medtronic), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick
   Pharmaceuticals (acquired by Lundbeck), Sadra Medical (acquired by Boston
   Scientific), and Threshold Pharmaceuticals (THLD). Mr. Galletti previously
   served on advisory boards for the Innovation and New Ventures Office at
   Northwestern University and the Life Sciences Advisory Board of Silicon
   Valley Bank. Mr. Galletti holds an MBA in Finance and Health Services
   Management from the Kellogg School of Management at Northwestern University
   and an AB from Princeton University.
   —
   Focus Areas: Medical Technology, Health Solutions
   Location: Menlo Park

 * CAROLYN
   
   HELMS

 * BRIAN
   
   LIU

 * MICHAEL
   
   WERT

 * MATTHEW
   
   YOUNG

   CAROLYN
   HELMS
   
   Managing Director and Chief Financial Officer
   
   Ms. Helms is a Managing Director and the Chief Financial Officer at Longitude
   Capital. Ms. Helms is responsible for the financial reporting of the Firm’s
   investment funds, as well as the day-to-day management of Firm-wide finance,
   tax, human resources, IT, and administration. In addition, Ms. Helms supports
   the Firm’s regulatory compliance program and works closely on legal, investor
   relations, and other operational matters. Ms. Helms served as the Firm’s
   Chief Compliance Officer from 2014 to September 2021. Prior to joining
   Longitude Capital in 2008, Ms. Helms was the Controller at Sierra Ventures, a
   venture capital firm focused on technology. Prior to Sierra Ventures, Ms.
   Helms was an Accounting Manager at NetManage, a publicly-traded software
   company, and was a Senior Auditor with Arthur Andersen LLP. Ms. Helms is a
   licensed CPA (inactive) and graduated cum laude with a BS in Business
   Administration (Accounting) from San Jose State University.
   —
   Focus Areas: Finance, Operations, Compliance
   Location: Menlo Park

   BRIAN
   LIU
   
   Managing Director
   
   Dr. Liu is a Managing Director at Longitude Capital. Prior to joining
   Longitude Capital in 2018, Dr. Liu was an Engagement Manager in the
   pharmaceuticals and medical products practice of McKinsey & Company. Dr. Liu
   currently serves on the board of CG Oncology and Lassen Therapeutics, and is
   a board observer at Quanta Therapeutics, and Zenas Biopharma. He previously
   served as a board observer at Dascena, Endeavor Biomedicines, Inflazome
   (acquired by Roche), Rivus Pharmaceuticals, Tourmaline Bio (TRML) (formerly
   known as Talaris Therapeutics (TALS)), and Vera Therapeutics (VERA), and was
   also actively involved in Longitude Capital’s investment in Strongbridge
   Biopharma (SBBP). Dr. Liu holds an MD from Stanford School of Medicine and a
   BS in Biomedical Engineering from The Johns Hopkins University.
   
   —
   Focus Areas: Biotechnology
   Location: Menlo Park

   MICHAEL
   WERT
   
   Managing Director
   
   Mr. Wert is a Managing Director at Longitude Capital. Mr. Wert was previously
   with Longitude Capital from 2008 to 2012 and rejoined in 2016. Before that,
   he was a Vice President at Warburg Pincus, where he focused on healthcare
   investments. Prior to joining Longitude Capital, Mr. Wert worked in the
   Global Healthcare Investment Banking Group at Merrill Lynch. Mr. Wert
   currently serves on the board of Cortica, On Belay Health, and WelbeHealth,
   and is a board observer at Cohere Health and Murj. He previously served as a
   board observer at California Cryobank (acquired by GI Partners and now known
   as Generate Life Sciences) and Somatus, and was also actively involved in
   Longitude Capital’s investments in IntelyCare and NOCD. While at Warburg
   Pincus, Mr. Wert served as a board observer at Silk Road Medical (SILK),
   Outset Medical (OM), and Accriva Diagnostics (acquired by Werfen). Mr. Wert
   holds an MBA from Stanford Graduate School of Business, where he was an
   Arbuckle Leadership Fellow and received a Certificate in Social Innovation
   and Public Management. He received his dual-degree BA in Biochemistry,
   Biophysics, and Molecular Biology (BBMB), and Economics with honors from
   Whitman College, graduating magna cum laude and Phi Beta Kappa.
   —
   Focus Areas: Health Solutions
   Location: Menlo Park

   MATTHEW
   YOUNG
   
   Managing Director
   
   Mr. Young is a Managing Director of Longitude Capital. Prior to joining
   Longitude Capital in 2022, Mr. Young was the Chief Operating Officer and
   Chief Financial Officer of GRAIL, a developer of blood cancer tests that was
   acquired by Illumina (ILMN) for $8 billion in 2021. From 2013 to 2019, Mr.
   Young held positions of increasing responsibility at Jazz Pharmaceuticals
   (JAZZ), a Longitude portfolio company, most recently as Executive Vice
   President and Chief Financial Officer. Prior to Jazz, Mr. Young was an
   investment banker for nearly 20 years at Barclays Capital, Citigroup, Lehman
   Brothers, and Merrill Lynch, where he advised and led financings for hundreds
   of emerging and established life science companies. Additionally, Mr. Young
   served on the board of PRA Health Sciences (PRAH) until its acquisition by
   ICON plc for $12 billion in 2021, and currently serves as Lead Independent
   Director and Chairman of the Audit Committee of CytomX Therapeutics (CTMX).
   Mr. Young also serves as a board member of Alpha-9 Therapeutics, Avenge Bio,
   and OrsoBio, and was actively involved in Longitude Capital’s investment in
   Mirum Pharmaceuticals (MIRM). Mr. Young holds an MBA and a BS in Economics
   from the Wharton School of the University of Pennsylvania.
   —
   Focus Areas: Biotechnology
   Location: Menlo Park


INVESTMENT PROFESSIONALS



 * NEIL
   
   ADVANI

 * BETHANY
   
   CHEN

 * ZACK
   
   ELY

 * VARUN
   
   GUPTA

   NEIL
   ADVANI
   
   Associate
   
   Mr. Advani is an Associate at Longitude Capital. Prior to joining Longitude
   Capital in 2024, Mr. Advani was an Investment Banking Analyst at Cowen, where
   he covered medical technology. He also was a Private Equity Analyst at
   Montage Partners prior to Cowen. Mr. Advani holds a BS in Accounting and a BS
   in Finance from the Arizona State University W. P. Carey School of Business.
   —
   Focus Areas: Medical Technology
   Location: Menlo Park

   BETHANY
   CHEN
   
   Associate
   
   Ms. Chen is an Associate at Longitude Capital. Prior to joining Longitude
   Capital in 2024, Ms. Chen was an Investment Banking Analyst at Morgan Stanley
   in the Healthcare group, where she focused on the biopharmaceutical sector.
   Ms. Chen holds a MS in Biology and a BS in Human Biology with a minor in
   Management Science and Engineering from Stanford University.
   —
   Focus Areas: Biotechnology
   Location: Boston

   ZACK
   ELY
   
   Senior Associate
   
   Dr. Ely is a Senior Associate at Longitude Capital. Prior to joining
   Longitude Capital full-time in 2022, Dr. Ely was a Longitude Research Fellow.
   Dr. Ely’s work has been published in several leading journals, including
   Nature Biotechnology, Cancer Cell, and Nature Cancer. Dr. Ely serves as a
   board observer at Alpha-9 Theranostics. Dr. Ely earned a PhD in Biology from
   the Massachusetts Institute of Technology, where he specialized in genome
   engineering and cancer immunology, and a BA in Molecular and Cellular Biology
   from Vanderbilt University.
   —
   Focus Areas: Biotechnology
   Location: Boston

   VARUN
   GUPTA
   
   Principal
   
   Mr. Gupta is a Principal at Longitude Capital. Prior to joining Longitude
   Capital in 2020, Mr. Gupta was a Consultant in the MedTech practice at L.E.K.
   Consulting, where he focused on growth strategy and M&A for corporate and
   private equity clients in the medical device industry. Mr. Gupta currently
   serves as a board observer at Endogenex and Nalu Medical, and was actively
   involved in Longitude Capital’s investments in Ceribell, Eargo (EAR),
   LimFlow, PROCEPT BioRobotics (PRCT), and an undisclosed medical technology
   company. He holds a BS and MS in Biomedical Engineering from the Robert R.
   McCormick School of Engineering and Applied Science at Northwestern
   University.
   —
   Focus Areas: Medical Technology
   Location: Menlo Park

 * DAVID
   
   HIRSCH

 * CINDY
   
   HU

 * MAGGIE
   
   JAMISON

 * TAIWAY
   
   KYON

   DAVID
   HIRSCH
   
   Venture Partner
   
   Dr. Hirsch is a Venture Partner and Founder of Longitude Capital. Prior to
   Longitude Capital, Dr. Hirsch was a Vice President of Pequot Ventures, where
   he worked in the healthcare practice. Prior to Pequot Ventures, Dr. Hirsch
   was an Engagement Manager in the pharmaceutical practice of McKinsey &
   Company. Dr. Hirsch is the CEO of Alpha-9 Theranostics, in addition to
   serving on the board of Rapid Micro Biosystems (RPID). Selected prior board
   memberships include Amunix Pharmaceuticals (acquired by Sanofi), Civitas
   Therapeutics (acquired by Acorda), Collegium Pharmaceutical (COLL), Inflazome
   (acquired by Roche), Molecular Templates (MTEM), Poseida Therapeutics (PSTX),
   Precision Therapeutics, Tricida (TCDA), Velicept Therapeutics, and Zavante
   Therapeutics (acquired by Nabriva (NBVA)). Dr. Hirsch also led Longitude
   Capital’s investments in Amarin (AMRN) and Cadence Pharmaceuticals (CADX,
   acquired by Mallinckrodt (MNK)). Dr. Hirsch holds a PhD in Biology from the
   Massachusetts Institute of Technology, an MD from Harvard Medical School, and
   a BA in Biology from The Johns Hopkins University.
   —
   Focus Areas: Biotechnology
   Location: Boston

   CINDY
   HU
   
   Associate
   
   Ms. Hu is an Associate at Longitude Capital. Prior to joining Longitude
   Capital in 2022, Ms. Hu was an Investment Banking Analyst at JP Morgan, where
   she covered biotechnology and pharmaceutical companies. Ms. Hu holds a BA in
   Economics from the University of Chicago.
   —
   Focus Areas: Biotechnology
   Location: Boston

   MAGGIE
   JAMISON
   
   Manager of Investor Relations & Marketing
   
   Ms. Jamison is a Manager of Investor Relations and Marketing at Longitude
   Capital. Prior to joining Longitude Capital in 2019, Ms. Jamison was an
   Account Manager at BBDO serving the Allergan and Bayer Crop Science accounts,
   where she led the development and launch of multi-channel marketing
   campaigns. Ms. Jamison holds a BA in Marketing and International Business
   from the University of Georgia.
   —
   Focus Areas: Investor Relations & Marketing
   Location: Menlo Park

   TAIWAY
   KYON
   
   Associate
   
   Mr. Kyon is an Associate at Longitude Capital. Prior to joining Longitude
   Capital in 2022, Mr. Kyon was an Associate at DNA Capital, a healthcare
   venture capital firm. Before that, he was an Investment Banking Analyst at
   Guggenheim Partners, where he covered medical devices. Mr. Kyon holds a BS in
   Business with a concentration in Finance and Statistics from the New York
   University Leonard N. Stern School of Business.
   —
   Focus Areas: Health Solutions
   Location: Menlo Park

 * VICTORIA
   
   LAI

 * ROD
   
   LIM

 * TRUDY
   
   VANHOVE

 * CINDY
   
   WANG

   VICTORIA
   LAI
   
   Vice President
   
   Ms. Lai is a Vice President at Longitude Capital. Prior to joining Longitude
   Capital in 2021, Ms. Lai was an Investor at HealthQuest Capital, a healthcare
   venture growth investment firm, where she executed investments across
   growth-stage healthcare companies including Everly Health, Thirty Madison,
   and ENT Specialty Partners. Prior to HealthQuest Capital, Ms. Lai was a
   Director at CarePoint Health System, where she held roles in strategy and
   operations and helped to build and run value-based care organizations. She
   also worked in the Healthcare Investment Banking Group at Goldman Sachs. Ms.
   Lai is a board observer at Cortica, NOCD, On Belay Health Solutions, and
   WelbeHealth. She was also actively involved in Longitude Capital’s investment
   in IntelyCare. Ms. Lai holds an MBA from Columbia Business School and a BA in
   Human Biology from Stanford University.
   —
   Focus Areas: Health Solutions
   Location: Menlo Park

   ROD
   LIM
   
   Senior Analyst – Public Equities
   
   Dr. Lim is a Senior Analyst focusing on public equities at Longitude Capital.
   Prior to joining Longitude Capital in 2024, Dr. Lim was an Analyst at Deep
   Track Capital, Lynx1, and Walleye Capital, where he focused on biotechnology
   long/short public equities. Prior to that, Dr. Lim was an Investment Banking
   Vice President at Jefferies, where he covered healthcare companies. Dr. Lim
   holds a PhD in Neurobiology from California Institute of Technology, and an
   MS in Cancer Immunology and a BS in Molecular Biology from the University of
   California, San Diego.
   —
   Focus Areas: Biotechnology
   Location: Boston

   TRUDY
   VANHOVE
   
   Venture Partner
   
   Dr. Vanhove is a Venture Partner at Longitude Capital. Dr. Vanhove has more
   than 25 years of clinical drug development and medical affairs experience
   across small and large biopharmaceutical companies. Prior to joining
   Longitude Capital in 2023, Dr. Vanhove most recently served as Chief Medical
   Officer of Surrozen (SRZN), a biotechnology company focused on discovering
   and developing novel regenerative medicines. Prior to Surrozen, Dr. Vanhove
   served as Vice President, Medical Affairs and, subsequently, Vice President
   of Search and Evaluation at Jazz Pharmaceuticals (JAZZ), a Longitude
   portfolio company. Prior to Jazz Pharmaceuticals, she served as Vice
   President, Medical Affairs at Depomed, Vice President, Clinical Development
   at NeurogesX, and a Medical Director at XOMA. She began her career as a
   Medical Director at Abbott Laboratories. Dr. Vanhove holds an MD and a PhD in
   Pharmacology from the Catholic University in Leuven, Belgium. She completed a
   fellowship in clinical pharmacology at Stanford University and holds an MBA
   from St. Mary’s College. Dr. Vanhove has authored, or co-authored, dozens of
   peer-reviewed articles, and is an inventor of numerous patents.
   —
   Focus Areas: Biotechnology
   Location: Menlo Park

   CINDY
   WANG
   
   Vice President
   
   Dr. Wang is a Vice President at Longitude Capital. Prior to joining Longitude
   Capital in 2022, Dr. Wang was the Senior Director of Strategy & Corporate
   Development at Dascena, a Longitude portfolio company. Prior to Dascena, Dr.
   Wang was an Engagement Manager at L.E.K. Consulting, where she consulted life
   sciences companies on drug development, commercial, and portfolio strategy.
   Dr. Wang currently serves as a board observer at CuraSen Therapeutics,
   Endeavor Biomedicines, Epirium Bio, Lassen Therapeutics, and Orbus
   Therapeutics. Dr. Wang holds a PhD in Chemical Biology from the University of
   California, Berkeley, and a BA in Chemical and Physical Biology from Harvard
   University.
   —
   Focus Areas: Biotechnology
   Location: Menlo Park

 * ANJA
   
   ZEHFUSS

   ANJA
   ZEHFUSS
   
   Research Analyst
   
   Ms. Zehfuss is a Research Analyst at Longitude Capital. Prior to joining
   Longitude Capital in 2022, Ms. Zehfuss assisted Draper Associates, an
   early-stage venture capital firm, in identifying potential investment
   opportunities through the University of Oxford start-up ecosystem. Ms.
   Zehfuss holds a MPhil from the University of Oxford and a BS in Human Biology
   from Stanford University.
   —
   Focus Areas: Health Solutions
   Location: Menlo Park


OPERATIONS



 * TERESA
   
   CABREROS

 * ROSE
   
   CARUSO WILSON

 * LISA
   
   CHUI

 * NICOLE
   
   GIVENS

   TERESA
   CABREROS
   
   Controller - Operations & Tax
   
   Ms. Cabreros is a Controller – Operations & Tax at Longitude Capital. Prior
   to joining Longitude in 2017, Ms. Cabreros was the Tax Controller at
   Northgate Capital. Ms. Cabreros started her career with
   PricewaterhouseCoopers LLP, as a Senior Tax Accountant in the Venture Capital
   Group, which led to a finance position at ONSET Ventures, an early-stage
   venture capital investment firm focused on the information and medical
   technology sectors. During her tenure at ONSET, Ms. Cabreros was a Senior
   Accountant, Accounting Manager, and Assistant Controller. Ms. Cabreros holds
   a BA in Economics with an emphasis in Accounting from the University of
   California, Santa Cruz.
   —
   Location: Menlo Park

   ROSE
   CARUSO WILSON
   
   Compliance and Legal Associate
   
   Ms. Caruso Wilson is a Compliance and Legal Associate at Longitude Capital.
   Prior to joining Longitude Capital in 2022, Ms. Caruso Wilson was a
   Compliance Consultant at ACA Global (formerly known as ACA Compliance), where
   she advised SEC-registered investment advisers on U.S. federal securities
   laws and helped develop and administer regulatory compliance programs for her
   clients. Ms. Caruso Wilson received her JD from the University of San
   Francisco School of Law and holds a BA in Political Science with a double
   minor in Criminology and Italian Language and Culture Studies from Marquette
   University.
   —
   Focus Areas: Legal, Compliance
   Location: Menlo Park

   LISA
   CHUI
   
   VP of People
   
   Ms. Chui is a VP of People at Longitude Capital. Prior to joining Longitude
   Capital in 2022, Ms. Chui was a VP, Head of People at Dascena, a Longitude
   Capital portfolio company. Ms. Chui is PHR certified and holds a BA in
   Communications from the University of Massachusetts, Amherst. — Focus Areas:
   Human Resources Location: Menlo Park

   NICOLE
   GIVENS
   
   Executive Assistant
   
   Ms. Givens is an Executive Assistant at Longitude Capital supporting the
   Medical Technology and Investment Relations teams as well as the CFO. Prior
   to joining Longitude in 2019, Ms. Givens was an Executive Assistant at Egon
   Zehender supporting Consultants. Previously, Ms. Givens was an Executive
   Assistant at Omidyar Network. Ms. Givens holds a BA in Communications from
   San Jose State University.
   —
   Location: Menlo Park

 * LAUREN
   
   HELENE

 * STEPHANIE
   
   HOLMAN

 * NICOLE
   
   HUGHES

 * JEFF
   
   JONSON

   LAUREN
   HELENE
   
   Executive Assistant
   
   Ms. Helene is an Executive Assistant at Longitude Capital, supporting the
   Health Solutions, Medical Technology, and Finance teams. Prior to joining
   Longitude Capital in 2023, Ms. Helene was an Executive Assistant at
   Freshfields Bruckhaus Deringer. Previously, Ms. Helene was an Executive
   Assistant at Vedder Price. Ms. Helene holds a MSt in International Relations
   from the University of Cambridge and a BA in History from the University of
   California, San Diego.
   —
   Location: Menlo Park

   STEPHANIE
   HOLMAN
   
   Controller
   
   Ms. Holman is a Controller at Longitude Capital. Prior to joining Longitude
   Capital in 2013, Ms. Holman was an Audit Associate with Moss Adams LLP and
   PricewaterhouseCoopers LLP, where she served technology and life sciences
   companies, as well as venture capital firms. Ms. Holman holds a BS in
   Microbiology from San Jose State University and a Certificate of Advanced
   Accounting Proficiency from Santa Clara University.
   —
   Location: Menlo Park

   NICOLE
   HUGHES
   
   Executive Assistant
   
   Ms. Hughes is an Executive Assistant at Longitude Capital supporting both the
   Biotechnology and Medical Technology teams. Prior to joining Longitude
   Capital in 2007, Ms. Hughes was an Executive Assistant at Pequot Ventures.
   Previously, Ms. Hughes served as an Executive Assistant at Pollock Financial
   Group. Ms. Hughes holds a BA in Sociology from Menlo College.
   —
   Location: Menlo Park

   JEFF
   JONSON
   
   Director of IT
   
   Mr. Jonson is the Director of IT at Longitude Capital. Prior to joining
   Longitude Capital in 2023, Mr. Jonson worked for AllCovered, where he held
   roles as Senior Systems Engineer, Engineering Team Lead, and Senior
   Professional Services Engineer. Mr. Jonson has over 15 years of work
   experience at Managed IT Service Providers and several venture capital firms,
   where he managed and oversaw IT operations. Mr. Jonson holds a BS in Network
   Communications Management from DeVry University, Fremont.
   —
   Focus Areas: IT
   Location: Menlo Park

 * KAREN
   
   LOK

 * DEBRA
   
   MERCADO

 * SEINI
   
   MOIMOI

 * CRISTIANA
   
   OLIVEIRA

   KAREN
   LOK
   
   Vice President of Finance
   
   Ms. Lok is a Vice President of Finance at Longitude Capital. Prior to joining
   Longitude Capital in 2015, Ms. Lok spent seven years at KPMG LLP (formerly
   Rothstein Kass) in audit and assurance, with a focus on life science venture
   capital funds. Ms. Lok holds a BA in Economics with an emphasis in Accounting
   from the University of California, Santa Barbara.
   —
   Location: Menlo Park

   DEBRA
   MERCADO
   
   Staff Accountant
   
   Ms. Mercado is a Staff Accountant at Longitude Capital. Ms. Mercado was
   previously with Longitude Capital from 2011 to 2016 and rejoined in 2019.
   Prior to initially joining Longitude in 2011, Ms. Mercado was a Senior Tax
   Associate at Frank, Rimerman + Co. LLP, where she served the tax needs of
   small investment companies as well as venture capitalists. Ms. Mercado is a
   licensed CPA and holds a BS in Business Administration from California
   Polytechnic State University, San Luis Obispo with a Concentration in Public
   Accounting.
   —
   Location: Menlo Park

   SEINI
   MOIMOI
   
   IRM & Administrative Assistant
   
   Ms. Moimoi is an Assistant to the Investor Relations & Marketing and
   Administration teams. Prior to joining Longitude Capital in 2017, Ms. Moimoi
   was a mentor and representative at the LEMO Foundation, a non-profit
   organization that works with at-risk youth. Ms. Moimoi holds a BA in
   Marketing from the University of Mississippi.
   —
   Location: Menlo Park

   CRISTIANA
   OLIVEIRA
   
   Head of Legal and Chief Compliance Officer
   
   Ms. Oliveira is the Head of Legal as well as the Chief Compliance Officer at
   Longitude Capital. Prior to joining Longitude Capital in 2020, Ms. Oliveira
   was a Senior Associate at Weil, Gotshal & Manges LLP, where she counseled
   public and private companies, private equity firms, and venture funds in a
   wide range of matters, including mergers and acquisitions, securities law
   compliance, venture financings, and commercial arrangements. Ms. Oliveira
   graduated with highest honors from the University of California, Berkeley
   with a BA in Political Science and received a JD from the University of
   California, Berkeley, School of Law.
   —
   Focus Areas: Legal, Compliance
   Location: Menlo Park

 * ERIN
   
   WRIGHT

   ERIN
   WRIGHT
   
   Executive Assistant
   
   Ms. Wright is an Executive Assistant at Longitude Capital. Prior to joining
   Longitude in 2018, Ms. Wright owned a Bar Method fitness studio. Previously,
   she worked in production at ABC News 20/20. Ms. Wright holds a BA in
   Communications from Fordham University.
   —
   Location: Greenwich


INVESTING IN HEALTHCARE INNOVATION

Longitude Capital invests in biotechnology, medical technology, and health
solutions companies that seek to improve clinical outcomes, enhance patient
quality of life, and reduce the cost of care. From start-ups to growth equity
investments, we are dedicated to helping management teams achieve technical,
clinical, and commercial milestones to create value and deliver attractive
returns to our limited partners.


PORTFOLIO

View All Biotechnology Medical Technology Health Solutions View All
Biotechnology: Breakthrough therapeutics and diagnostics that improve clinical
care.
Medical Technology: Devices and solutions that leverage miniaturization, data
connectivity, and process automation.
Health Solutions: Emerging care models and coordination platforms that improve
access, outcomes, and efficiency.
89bio
89Bio is a biopharmaceutical company focused on nonalcoholic steatohepatitis
(NASH) and other liver and metabolic disorders.
Status: current
Visit Site
AEON Biopharma
AEON Biopharma (formerly known as Alphaeon) is a clinical-stage
biopharmaceutical company focused on developing a proprietary botulinum toxin
complex for the treatment of multiple debilitating medical conditions.
Status: current
Visit Site
Aimmune Therapeutics
Aimmune is a biopharmaceutical company developing oral immunotherapies to treat
acute food allergies.
Status: exited
Visit Site
Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on delivering
innovative therapies to patients with kidney disease.
Status: exited
Visit Site
Alpha-9
Alpha-9 Oncology is a biotechnology company developing imaging and therapeutic
molecules for the treatment of solid and hematologic cancers.
Status: current
Visit Site
Amarin Corporation
Amarin is a biopharmaceutical company focused on the commercialization and
development of therapeutics to improve cardiovascular health.
Status: exited
Visit Site
Amphora Medical
Amphora is a medical technology company developing devices to treat overactive
bladder.
Status: exited

Amunix Pharmaceuticals
Amunix Pharmaceuticals is a biopharmaceutical company intended to discover,
design and develop novel biologics, protein and peptide therapeutics.
Status: exited
Visit Site
Aptinyx
Aptinyx is a biotechnology company developing innovative therapies for
neurological disorders.
Status: exited
Visit Site
Aptus
Aptus was a medical technology company that developed helical anchor technology
for improved endovascular aneurysm repair. Aptus was acquired by Medtronic in
2015.
Status: exited

Aquesys
AqueSys was a medical technology company developing implantable devices for the
treatment of glaucoma. AqueSys was acquired by Allergan in 2015.
Status: exited

Avenge Bio
Avenge Bio is a biotechnology company developing the LOCOcyteTM cell-therapy
platform for continuous local dosing of immunotherapeutics.
Status: current
Visit Site
Axonics Modulation Technologies
Axonics is a medical technology company developing a miniaturized rechargeable
implantable neuromodulation technology to treat urinary and fecal dysfunction.
Status: exited
Visit Site
BAROnova, Inc.
BAROnova is a medical technology company developing endoscopically-delivered
devices for the treatment of obesity.
Status: exited
Visit Site
BioAge
BioAge is a clinical-stage biotechnology company developing novel therapies for
obesity and metabolic diseases discovered by harnessing the biology of aging.
Status: current
Visit Site
Bolt Medical
Bolt Medical is a medical technology company developing a next-generation IVL
(intravascular lithotripsy) device built on a laser-based platform for the
minimally invasive treatment of narrowed calcified arteries.
Status: current
Visit Site
Cadence Pharmaceuticals
Cadence was a specialty pharmaceutical company that developed and marketed
Ofirmev, an intravenous form of acetaminophen for pain management. Cadence was
acquired by Mallinckrodt in 2014.
Status: exited

CardioDx
CardioDx is a biotechnology company that markets genomic tests to help
cardiologists assess and treat cardiovascular disease.
Status: exited

Ceribell
Ceribell is a medical technology company that developed the Rapid Response EEG™,
a novel non-invasive brain monitor.
Status: current
Visit Site
CG Oncology
CG Oncology is a biotechnology company developing oncolytic immunotherapies for
patients with advanced cancer.
Status: current
Visit Site
Checkmate Pharmaceuticals
Checkmate Pharmaceuticals is a biotechnology company that develops cancer
immunotherapies designed to recognize and destroy tumor cells.
Status: exited
Visit Site
Civitas Therapeutics
Civitas was a biopharmaceutical company developing CVT-301, a potentially
transformative therapy for people with Parkinson’s disease. Civitas was acquired
by Acorda Therapeutics in 2014.
Status: exited

Cohere Health
Cohere is an emerging high growth digital health company with solutions to
fundamentally transform utilization management in order to drive truly
collaborative care journeys.
Status: current
Visit Site
Collegium Pharmaceutical
Collegium is a biotechnology company developing abuse-deterrent pharmaceutical
products for chronic pain.
Status: exited
Visit Site
Corcept Therapeutics
Corcept is a biotechnology company developing pharmaceuticals for patients with
severe metabolic and oncologic disorders.
Status: exited
Visit Site
Cortica
Cortica is a technology-enabled company providing holistic solutions for
children with autism and other neurodevelopmental conditions.
Status: current
Visit Site
CrownWheel Partners, LLC
CrownWheel Partners provides liquidity and financing solutions to royalty owners
and companies in the global healthcare sector.
Status: current
Visit Site
CuraSen Therapeutics
CuraSen Therapeutics is focused on the discovery and development of therapies to
treat neurodegenerative diseases.
Status: current
Visit Site
Cydan Development
Cydan is an orphan drug accelerator focused on identifying and de-risking
programs with therapeutic and commercial potential.
Status: exited

Dascena
Dascena is a machine learning company developing algorithms as predictive
biomarkers for complex medical conditions.
Status: exited
Visit Site
Eargo
Eargo is a medical technology company that sells a virtually invisible,
innovative hearing aid directly to the consumer.
Status: exited
Visit Site
Encore Dermatology
Encore Dermatology is a specialty pharmaceutical company that acquires and
manages prescription dermatology assets for both cosmetic and medical
procedures.
Status: exited

Endeavor BioMedicines
Endeavor BioMedicines is a biotechnology company developing new treatments for
idiopathic pulmonary fibrosis.
Status: current
Visit Site
Endogenex
Endogenex is developing therapies for GI and metabolic disease processes.
Status: current
Visit Site
Epirium Bio
Epirium Bio (formerly known as Cardero) is a clinical-stage biopharmaceutical
company developing therapeutics that promote mitochondrial biogenesis and
function.
Status: current
Visit Site
Esperion Therapeutics
Esperion is a biotechnology company developing oral, low-density, lipoprotein
cholesterol (LDL-C) lowering therapies to treat hypercholesterolemia without
statins.
Status: exited
Visit Site
Generate Life Sciences
Generate Life Sciences (formerly known as California Cryobank Life Sciences) is
a technology-enabled healthcare company that provides cellular services for both
the fertility and cellular therapy sectors.
Status: exited
Visit Site
InfaCare Pharmaceutical
InfaCare is a biotechnology company developing the only pharmacologic treatment
for infantile jaundice.
Status: exited

Inflazome
Inflazome is developing a portfolio of NLRP3 inhibitors to treat inflammation
driven diseases.
Status: exited
Visit Site
Inozyme Pharma
Inozyme Pharma is a biotechnology company developing new medicines to treat rare
disorders of calcification.
Status: current
Visit Site
IntelyCare
IntelyCare is a health solutions company that has developed a tech-enabled
solution to meet the needs of nurses and healthcare provider organizations.
Status: current
Visit Site
Jazz Pharmaceuticals
Jazz is a biotechnology company developing and marketing specialty
pharmaceuticals for a variety of neurological and oncologic conditions.
Status: exited
Visit Site
KALA BIO
KALA BIO (Nasdaq: KALA) is a biotechnology company developing innovative
nanoparticle-based treatments for ocular diseases affecting both front and back
of the eye.
Status: current
Visit Site
KaNDy Therapeutics
KaNDy is developing NT-814 for the treatment of common, chronic debilitating
female sex-hormone related conditions, with an initial focus on symptoms of the
menopause.
Status: exited

Lassen Therapeutics
Lassen Therapeutics is a biotechnology company developing first-in-class
monoclonal antibodies (mAb) targeting the IL-11 receptor (IL-11R), a central
mediator of fibrosis and inflammation.
Status: current
Visit Site
Lexeo Therapeutics
Lexeo Therapeutics is a biotechnology company developing a pipeline of gene
therapies for rare and non-rare monogenic diseases.
Status: current
Visit Site
LimFlow
LimFlow is a medical device company developing a minimally-invasive technology
for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of
peripheral artery disease (PAD).
Status: exited
Visit Site
Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming
the treatment of rare liver diseases.
Status: current
Visit Site
Molecular Templates
Molecular Templates is focused on the discovery, development and
commercialization of next generation immunotoxins called Engineered Toxin Bodies
for the treatment of cancer.
Status: current

Murj
Murj is a technology-enabled healthcare company developing and marketing a
cloud-based SaaS platform to help clinicians streamline and improve care for
patients with implantable cardiac devices.
Status: current
Visit Site
Nabriva Therapeutics
Nabriva is a biotechnology company focused on the development of novel
anti-infective agents to treat serious infections.
Status: exited
Visit Site
Nalu Medical
Nalu is a medical technology company developing next-generation
neuro-stimulation devices for pain.
Status: current
Visit Site
Neurana Pharmaceuticals
Neurana is a biotechnology company developing tolperisone, a novel, patented
skeletal muscle relaxant for the treatment of acute, painful muscle spasms
without sedation.
Status: exited

NOCD
NOCD is a health solutions company providing a digital platform to identify and
manage obsessive-compulsive disorder.
Status: current
Visit Site
NxStage Medical
NxStage is a medical technology company that developed and markets the System
One, a device for home-based nocturnal hemodialysis therapy.
Status: exited
Visit Site
On Belay Health Solutions
On Belay is a health solutions company that partners with primary care practices
to provide clinical and administrative support that enables the practices to
move into value-based care arrangements.
Status: current
Visit Site
Opna Bio
Opna Bio is a biotechnology company focused on discovering and developing small
molecule inhibitors of a novel target, FMRP (fragile X mental retardation
protein), for cancer immunotherapy.
Status: current
Visit Site
Orbus Therapeutics
Orbus is a biotechnology company developing pharmaceutical products for the
treatment of brain tumors.
Status: current
Visit Site
OrsoBio
OrsoBio is a biopharmaceutical company developing oral treatments for metabolic
disorders.
Status: current
Visit Site
PixelOptics
PixelOptics was a medical technology company developing the world’s first
electronically focusing progressive lens to move automatically between a user’s
optimal near and far vision prescriptions.
Status: exited

Polares Medical
Polares Medical is a medical technology company with a novel device for treating
mitral valve regurgitation.
Status: current
Visit Site
Poseida Therapeutics
Poseida is translating best-in-class gene engineering technologies into CAR
T-cell immunotherapies for multiple myeloma, prostate and other cancers, as well
as gene therapies for orphan diseases.
Status: current
Visit Site
Practice Fusion
Practice Fusion is a technology-enabled healthcare services company that
provides a cloud-based electronic health record platform to connect doctors,
patients and data to drive better health.
Status: exited
Visit Site
Precision Dermatology
Precision Dermatology was a specialty pharmaceutical company that sold both
prescription and non-prescription skin care products. The company was acquired
by Valeant Pharmaceuticals in 2014.
Status: exited

Precision Therapeutics
Precision Therapeutics (now Helomics) markets diagnostic assays that help
oncologists recommend chemotherapy regimens tailored to patients’ specific tumor
genetics.
Status: exited
Visit Site
PROCEPT BioRobotics
PROCEPT BioRobotics is a medical technology company developing surgical robotics
to provide transformative solutions in urology.
Status: exited

Quanta Therapeutics
Quanta Therapeutics is a biotechnology company developing precision therapies
for RAS-driven cancers.
Status: current
Visit Site
Rapid Micro Biosystems
Rapid Micro Biosystems creates, markets, validates and services innovative
products to detect microbial contamination in the manufacture of
pharmaceuticals, biologics, biotechnology products, medical devices and personal
care.
Status: current
Visit Site
Renew Medical
Renew is a medical technology company developing disposable devices to prevent
accidental bowel leakage.
Status: exited

RxSight
RxSight is a medical technology company developing adjustable intraocular lenses
for cataract surgery.
Status: exited
Visit Site
Sierra Oncology
Sierra Oncology is a biotechnology company developing therapeutics for the
treatment of hematology and oncology.
Status: exited
Visit Site
Solta Medical
Solta was a medical technology company that developed and marketed energy-based
devices for a variety of aesthetic applications. Solta was acquired by Valeant
Pharmaceuticals in 2014.
Status: exited
Visit Site
Somatus
Somatus is a healthcare service company providing concierge kidney care intended
to delay or prevent the progression of chronic kidney disease (CKD) to ESRD.
Status: current
Visit Site
Sublimity Therapeutics
Sublimity Therapeutics is a biotechnology company developing therapies for the
treatment of ulcerative colitis.
Status: exited

Sydnexis
Sydnexis Inc. is a biopharmaceutical company developing therapies for the
treatment of progressive myopia in children.
Status: current
Visit Site
Sympara Medical
Sympara was a medical technology company developing a wearable, non-invasive
medical device to reduce blood pressure in hypertensive patients.
Status: exited

Theseus Pharmaceuticals
Theseus Pharmaceuticals is a biotechnology company developing pan-variant
tyrosine kinase inhibitors designed to overcome treatment-resistant cancer.
Status: exited

Tourmaline
Tourmaline is a biotechnology company developing innovative cellular therapies
for organ transplantation and severe auto-immune disorders.
Status: current
Visit Site
Tricida
Tricida is a biotechnology company focused on the development of therapies for
patients with chronic kidney disease.
Status: exited
Visit Site
Twelve, Inc.
Twelve was a medical technology company developing devices for transcatheter
mitral valve replacement. Twelve was acquired by Medtronic in 2015.
Status: exited

Vaxcyte
Vaxcyte (formerly known as SutroVax) is a biotechnology company developing
conjugate and protein-based vaccines for infectious diseases.
Status: exited
Visit Site
Velicept Therapeutics
Velicept is a biotechnology company developing pharmaceutical products for the
treatment of overactive bladder and irritable bowel syndrome.
Status: exited

Velomedix
Velomedix was a medical technology company developing devices to induce mild
therapeutic hypothermia in heart attack and cardiac arrest patients.
Status: exited

Venus Concept
Venus Concept is a medical technology company that markets a suite of products
for the reduction of facial wrinkles, rhytides and cellulite.
Status: current
Visit Site
Vera Therapeutics
Vera Therapeutics is a clinical-stage biotechnology company focused on
developing treatments for immunological and inflammatory diseases.
Status: current
Visit Site
Viridian Therapeutics
Viridian Therapeutics is a biotechnology company developing new treatments for
patients suffering from serious diseases underserved by current therapies.
Status: current
Visit Site
WelbeHealth
WelbeHealth is an innovative healthcare services company delivering
comprehensive care to medically frail seniors, resulting in better outcomes at
lower cost.
Status: current
Visit Site
Xanodyne Pharmaceuticals
Xanodyne was a specialty pharmaceutical company marketing a range of pain
management therapies.
Status: exited

Xeris Biopharma
Xeris Biopharma (NASDAQ: XERS) is a biotechnology company developing and
commercializing unique therapies for patient populations in endocrinology,
neurology, and gastroenterology.
Status: current

Zenas BioPharma
Zenas BioPharma is a biopharmaceutical company developing innovative autoimmune
therapeutics.
Status: current
Visit Site


NEWS

Check out the latest news about Longitude Capital and our portfolio companies.

PORTFOLIO NEWS

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013


Apr 17Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an
AAV-Based Gene… Apr 10Opna Bio Presents Promising Preclinical Data in Multiple
Myeloma with OPN-6602 and… Apr 08Inozyme Pharma Announces Positive Topline Data
from Ongoing Phase 1/2 Trials of… Apr 03Cohere Health to Further Reduce
Administrative Burden for Providers via Epic’s Payer… Apr 02Mirum
Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive
Reimbursement Recommendation by Canada’s… Mar 13Mirum Pharmaceuticals’ LIVMARLI
Receives FDA Approval for Treatment of Cholestatic Pruritus in… Mar 13Lexeo
Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity
FinancingMar 07CuraSen Therapeutics Announces Oral Presentation of Additional
Positive Phase 2a Data with… Feb 27CG Oncology Announces First Patient Dosed in
PIVOT-006 Phase 3 Clinical Trial… Feb 13BioAge Announces $170 Million
Oversubscribed Series D Financing to Accelerate Development of…

Older

LONGITUDE CAPITAL NEWS

11.17.22Longitude Capital Expands Biotechnology Practice With Matthew Young,
Former Grail COO and… 11.02.22Longitude Capital Promotes Carolyn Helms, Chief
Financial Officer, to Managing Director07.20.21Longitude Capital Raises
Inaugural Opportunities Fund With $135 Million To Invest in… 03.04.21Healthcare
Venture Capital Firm Longitude Capital Promotes Brian Liu to
Principal09.23.20Longitude Capital Raises $585 Million Fund to Invest in
Transformative Healthcare Companies01.09.20Longitude Capital Promotes Max Bikoff
To Principal02.16.17Longitude Capital Promotes Josh Richardson, M.D. To Managing
Director06.07.16Longitude Capital Closes $525 Million Fund05.20.15Longitude
Capital Promotes Sandip K. Agarwala To Managing Director03.17.14Longitude
Capital Maintains Momentum with Promotions and Team Expansion

Older


CONTACT US



MENLO PARK

2740 Sand Hill Road, 2nd Floor
Menlo Park, CA 94025
650.854.5700
Click here for directions

GREENWICH

55 Railroad Ave, Suite 101
Greenwich, CT 06830
203.769.5200
Click here for directions

BOSTON

607 Boylston Street, 6th Floor
Boston, MA 02116
617.841.2600
Click here for directions

 * Name*
   
 * Email*
   
 * Comment
   



Δ

 * Facebook
 * Twitter
 * Google
 * RSS



LP Login

© 2024 Longitude Capital. All rights reserved.
 * Privacy Policy
 * Disclaimer

Notifications